A GLP-1 in pill form from Eli Lilly shows promising results for weight loss and Type 2 diabetes treatment in a trial. FDA ...

Mounjaro weight loss jabs now available from GPs as NHS begins mass rollout - Around 29% of the adult population in the UK is ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also cause pregnancy complications and harm some users.

The weight loss and diabetes drug, which is only available on prescription, should be on pharmacy shelves within days ending ...

Both Wegovy and Ozempic are semaglutide – a drug that first entered the US market in 2017 as a diabetes medication. It was ...

Since the GLP-1 drugs, including Mounjaro, Ozempic and Wegovy, were licensed, there have been hundreds of reported cases of ...

A new trial has found that a weight loss drug taken monthly helps people lose 20 percent of their body weight. Weight loss medications such as Ozempic, Wegovy and Mounjaro have become popular and now ...

Mounjaro has been approved for both type 2 diabetes and weight loss; however, access will be limited by strict eligibility ...

Around 220,000 people with "greatest need" are expected to receive Mounjaro, also known as tirzepatide and made by Lilly ...

Prescriptions for Mounjaro jabs, to help people lose weight, will be available at GP surgeries in England from today - but ...